This week’s bulletin (which is coming a few days later than our usual Friday communiqué) offers a deep dive into COMPASS Pathways’ topline Phase 2b results, which were released last Tuesday. In this long-read piece we seek to begin contextualising the preliminary safety and efficacy data from this influential trial, and end by summarising the next steps for COMPASS. Topline results from COMPASS…
